It’s being expected that by 2030, the Parkinsons Disease Treatment market cap will hit USD 6,705 Million at a CAGR growth of about 11.5%.
The Parkinson’s disease treatment market growth was driven because of increase in the geriatric population and the rise in the occurrence of the Parkinson’s disease and the funding for research. Global Parkinson’s disease treatment market is anticipated to experience the substantial growth during the forecast period. Growth in the occurrence of the Parkinson’s diseases is projected to supplement the growth of global Parkinson’s disease treatment market in the coming future. In addition, the combined treatments supporting in the long action of constant dopaminergic stimulation medicines, neural transplantation and gene therapy is expected to fuel the Parkinson’s disease treatment market growth.
Parkinson’s disorder is a neurological disorder affecting the movements of body. There are five stages of this disease and can hamper the individual’s leg & hand movements, facial expressions getting worse with the growing age. Increase in the elderly population related to the rise in the investments in the activities of research & development, growth in the awareness for healthcare and the neurological disorders are the factors driving the global Parkinson’s disease treatment market growth over the forecast period. On the other hand, due to the presence of the other treatments is hampering the Parkinson’s disease treatment market growth.
Current developments in the Parkinson’s disease treatment, for example, combined treatment to continue the effect of constant dopaminergic stimulation medicines, gene therapy, neural transplantation, neuroprotective treatment to reduce the disease prediction and support for the neurostimulation tools are estimated to provide large development in the global Parkinson’s disease treatment market growth during the forecast period. Moreover, major characteristics that are fueling the requirement and demand for the global parkinson’s disease treatment market are prevalence of parkinson’s disease and growth in the geriatric population. Two important characteristics that are responsible to boost the Parkinson’s disease treatment market development are prevalence of the neurodegenerative syndrome and rise in the elderly population. Although, increase in the medicines in the pipeline and growth in the R&D activities are anticipated to surge the Parkinson’s disease treatment market size. In addition, lack of skills for the early diagnosis and large spending on treatment is projected to bolster the development of global Parkinson’s disease treatment market.
Key factor driving the growth of Parkinson’s disease treatment market is the growth in the acceptance of the treatment for Parkinson’ disease in healthcare sector. For treating and detecting the dysfunctioning of the human beings central nervous system and the neurological damage because of lack of cells and nerves are the main function of Parkinson’s disease treatment market.
Global Parkinson’s disease treatment market is segmented into end-use, distribution channel, drug class and region. Based on end-use, market is divided into clinics and hospitals. On the basis of distribution channel, market is divided into retail pharmacies, online pharmacies and hospital. On considering the drug class, market is divided into MAO inhibitors, Levopoda/ Carbidopa and Dopamine Receptor Agonists.
Geographically, regions involved in the development of Parkinson’s disease treatment market growth are Europe, North America and Asia Pacific. Asia Pacific is anticipated to show the rapid growth because of the increase in the trend of medical tourism and medical infrastructure. North America holds the largest Parkinson’s disease treatment market share. Europe is dominating the Parkinson’s disease treatment market because of the maximum market revenue in the coming years.
Key players involved in the Parkinson’s disease treatment market analysis are Teva Pharmaceutical Industries, Novartis AG, Impax Laboratories and GlaxoSmithKline.
Parkinsons Disease Treatment Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2030||USD 6,705 Million|
|Growth Rate||CAGR of 11.5% during 2021-2030|
|Segment Covered||by Drug Class, Regions|
|Regions Covered||North America, Europe, Asia Pacific, South America, Middle East and Africa|
|Key Players Profiled||GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH., Impax Laboratories LLC, AbbVie Inc., Bausch Health., Lundbeck, Sun Pharmaceutical Industries Ltd., ACADIA Pharmaceuticals Inc., Merck & Co. Inc., Novartis AG, UCB S.A., Dr. Reddy’s Laboratories Ltd., WOCKHARDT., F. Hoffmann-La Roche Ltd, STADA Arzneimittel AG, Orion Corporation., Mylan N.V., Cipla Inc., Par Pharmaceutical., DAIICHI SANKYO COMPANY LIMITED., and Apotex Inc, among other domestic and global players.|
Key Segments in the “Global Parkinson’s Disease Treatment Market” are-
By End-Use, market is segmented into:
By Distribution Channel, market is segmented into:
- Retail pharmacies
- Online pharmacies
By Drug Class, market is segmented into:
- MAO inhibitors
- Levopoda/ Carbidopa
- Dopamine Receptor Agonists.
By Regions market is segmented into:
- North America